A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of ZB716 as Monotherapy and in Combination With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 06 Mar 2024
At a glance
- Drugs Borestrant (Primary) ; Palbociclib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ENZENO
- Sponsors EnhancedBio
- 05 Jan 2023 According to Louisiana Cancer Research Center media release, Dr. Guangdi Wang the principal investigator of this trial received a $4 million investment to fund a phase 1 clinical trial of research drug ZB716 for patients with ER+/HER2 metastatic or advanced breast cancer
- 21 Apr 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Feb 2021 to 10 May 2021.
- 21 Apr 2021 Planned initiation date changed from 1 Feb 2021 to 10 May 2021.